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Could you begin by describing your primary 
research interests?
DY: I mainly study the pathophysiology of 
ischaemia-reperfusion and acute myocardial 
infarction, in both the basic and clinical setting. 
This involves investigating both ways to protect 
the heart and the molecular and cellular 
aspects of adaptation to ischaemic injury.
SD: My main research area overlaps with 
Yellon’s, being focused on the molecular aspects 
of cellular injury with specific attention to 
nanoparticles (exosomes) and their role in the 
cardiovascular system. I also specialise in using 
optical imaging to visualise cellular responses to 
injury and delineate the mechanisms involved in 
remote ischaemic conditioning (RIC).
How did you come to develop an interest 
in RIC? 
DY&SD: Myocardial preconditioning was 
discovered in 1986 by serendipity when 
investigators at Duke University, USA, 
demonstrated that short periods of loss 
and return of coronary blood flow could 
significantly protect the heart from a 
subsequent ischaemic insult. This phenomenon 
was shown to be the most powerful form 
of cardiac protection known to date and 
attracted leading investigators around the 
world (including ourselves) who wanted 
to elucidate its mechanisms and potential 
clinical significance. 
Importantly, we were the first to demonstrate 
that a non-invasive RIC method could protect 
the hearts of patients undergoing routine 
coronary artery bypass graft (CABG). We are 
pleased to state that we have now been given 
significant funding by the Medical Research 
Council (MRC), the National Institute for 
Health Research (NIHR) and the British Heart 
Foundation (BHF) to conduct the first multi-
centre outcome study to test the efficacy of this 
method in patients undergoing CABG.
What brought the potential cardioprotective 
role of exosomes to your attention? 
DY: Exosomes are nanoscale lipid vesicles that 
are released from multi-vesicular bodies in cells 
and are believed, under appropriate conditions, 
to act as carriers of protective proteins. Davidson 
came across their importance when, while 
trying to understand how messages could be 
transported from the RIC limb to the heart (or 
other organ under threat of injury), he learned of 
their ability to transport multiple proteins while 
evading the immune system. We immediately 
saw the potential that these nanoparticles may 
have as delivery vectors and undertook initial 
studies to investigate their ability to protect the 
heart from ischaemia-reperfusion injury. 
When studying exosomes, what challenges 
have you faced?
DY&SD: The first challenge we have faced was, 
simply, how to measure them; this is difficult as 
they are smaller than the wavelength of light 
and therefore can’t be seen using standard 
techniques. However, we became aware of 
recently developed specialised equipment that 
enables the detection of these nanoparticles 
using a technique involving laser diffraction. 
We immediately raised the funds to purchase 
this equipment, which allowed us to directly 
demonstrate that RIC stimulates the release of 
exosomes in animals and humans. 
Do researchers at the Hatter Cardiovascular 
Institute at University College London (UCL), 
where you are based, collaborate with other 
research groups?
DY&SD: We have established a number of 
productive collaborations. Within UCL, we 
are working closely with Professor Steve 
Humphries and Dr Natassa Kalea to investigate 
the ability of exosomes to deliver microRNA 
and reprogram cells. We are also investigating 
the cellular mitochondrial response, using 
multi-photon imaging, together with Professor 
Micheal Duchen. 
Internationally, we are working closely with 
Professor Jim Downey from the University 
of South Alabama, USA, investigating 
mitochondrial DNA and its detrimental 
role in inflammatory response. We are also 
collaborating with Dr Borja Ibanez from the 
Spanish National Centre for Cardiovascular 
Research in Madrid, whose large animal facilities 
will potentially enable us to translate our studies 
to a clinically relevant model.
Which of your professional achievements 
would you consider your greatest to date?
DY: My greatest professional achievement 
has been setting up the Hatter Cardiovascular 
Institute at UCL. What started out as a relatively 
small group of enthusiastic basic and clinical 
scientists has developed into an internationally 
recognised cardiovascular institute that houses 
approximately 50 scientists, clinicians and 
support staff, and is funded by major grants 
from the MRC, BHF, Wellcome Trust, NIHR 
Biomedical Research Centre, The Hatter 
Foundation and the Rosetrees Trust. The 
Institute’s ethos is very much focused on 
translational research related to whether it 
is possible to protect the heart during an acute 
myocardial infarction; we take treatments from 
the experimental basic science stage in our 
laboratories through to patients in the clinic. 
We are fortunate to have some of the world’s 
very best basic scientists, as well as a range 
of world-class clinical cardiovascular services 
through which to recruit patients for trials.
Professor Derek Yellon and Dr Sean Davidson discuss their 
research on preventing injury to the heart from ischaemia-
reperfusion and the potentially protective role of exosomes
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Natural heart protection
The Hatter Cardiovascular Institute is conducting the first 
multi-centre outcome trial of a simple, safe and non-invasive 
procedure to protect the heart from injury during coronary artery 
bypass surgery or heart attack, while investigating the cellular 
communication mechanisms that underlie its effectiveness
CORONARY HEART DISEASE, in which the 
arteries and small vessels that transport blood 
and oxygen to the heart become narrowed by 
fatty deposits of plaque building up along their 
walls, is currently the leading cause of death in 
the UK. Furthermore, as populations age and 
the incidence of risk factors such as obesity 
and diabetes continues to rise, it is predicted 
that the number of deaths caused by coronary 
heart disease will increase along with them. 
Of these deaths, the majority are caused by 
heart attacks.
Successful treatment for heart attack and 
during cardiac surgery, relies on the restoration 
of blood flow (reperfusion) of heart tissue. 
Ironically, however, the reperfusion procedure 
exacerbates the damage caused by ischaemia, 
which can be lethal to cells in the myocardium. 
Ischaemia and reperfusion injury thus bring 
about metabolic and structural changes to 
the heart, which can result in abnormal heart 
muscle function and lead to heart failure.
REMOTE POSSIBILITIES
For years it has been known that ischaemic 
preconditioning – a short reiteration of 
withdrawal and re-supply of blood to the heart 
– can protect against heart attack. However, as 
an invasive procedure, its use in heart surgery 
was limited. More recently, it was found that 
preconditioning applied to other tissues or 
visceral organs remote from the heart, such as 
the kidney, have equivalently protective effects 
for the heart, although this form of so-called 
remote ischaemic conditioning (RIC) was also 
invasive and so attracted few adherents among 
cardiologists and cardiac surgeons. According 
to Professor Derek Yellon, founder and Director 
of the Hatter Cardiovascular Institute at 
University College London (UCL), it was only 
recently that a non-invasive method of RIC was 
discovered and the prospect of its utilisation 
to routinely protect the heart from cell death 
during myocardial infarction or surgery became 
real: “Collaborators of ours at UCL found that 
a blood pressure cuff, placed on the upper arm 
or lower limb and inflated and deflated three or 
four times, resulted in a signal being sent to the 
heart to protect it during an ischaemic insult”. 
Since then, the effects of this low-cost, non-
invasive method of RIC have been explored in 
a number of studies using patients undergoing 
surgical procedures including coronary artery 
bypass graft (CABG), percutaneous coronary 
intervention and kidney transplantation; indeed, 
Yellon and his team at the Institute conducted the 
first proof-of-concept clinical study in patients 
undergoing scheduled CABG. Now, following 
on from findings that indicate non-invasive RIC 
may offer significant benefits in terms of one-
year post-operative survival of CABG, Yellon and 
colleagues are running the first large-scale trial of 
the approach in a study entitled ‘Effect of Remote 
Ischaemic preConditioning on clinical outcomes 
in patients undergoing Coronary Artery Bypass 
Graft surgery’ (ERICCA). 
ERICCA
The study is a multi-centre double blind trial 
of the effect of RIC on patient outcomes after 
receiving CABG with or without accompanying 
heart valve surgery. Heart valve surgery patients 
have been specifically included as, although 
typically higher risk, earlier proof-of-concept 
trials have clearly suggested that RIC may 
have a beneficial influence on the outcomes for 
such patients. 
1,610 adult patients calculated to be at high 
risk of death following heart surgery have been 
recruited for the study from 27 UK tertiary cardiac 
centres, with each being randomly given either a 
functional or dummy RIC procedure on the day of 
their operation. In all cases, four cycles of blood 
pressure cuff inflation/deflation are applied to 
the patient’s arm or leg after anaesthesia, prior 
to reperfusion and surgery. The research nurse 
undertaking this procedure is the only individual 
present in the cardiac centre who knows whether 
the cuff is operational or not, with all subsequent 
follow-ups, biomarker measurement and data 
collection being carried out by other staff.
The principal aim of ERICCA is to establish 
whether RIC improves patient outcomes in 
terms of subsequent fatality from cardiovascular 
causes, non-fatal heart attack or stroke, or 
the need for revascularisation, within both 
30 days and one year of surgery. ERICCA will 
also assess whether RIC reduces the extent of 
complications after surgery in terms of heart 
damage, maintenance of left ventricle systolic 
function and the development of acute kidney 
injury. Other measures will include RIC’s impact 
on the patient’s length of stay in intensive care 
and in hospital following the operation; whether 
post-operative fatalities from any cause are 
reduced; and whether there is any reduction in 
requirements for inotropic drugs to boost heart 
muscle contraction ability. Finally, ERICCA will 
A transgenic mouse heart glows green in response to calcium, enabling the team to visualise the response to ischaemia.
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carry out assessments of exercise tolerance (via 
a six minute walking test) and overall sense of 
quality of life on recruitment, six weeks after 
treatment, and then quarterly. 
TRACKING SIGNALLING
So far, animal and clinical trials have provided 
compelling evidence of the benefits of non-
invasive RIC. However, how the signal reaches 
the major organs from the limb that receives 
RIC and what mechanisms confer protection 
to the heart  remain unclear. One proposition is 
that a messenger molecule carried in the blood 
is the source; another is that the mechanism 
employs as yet undefined neural pathways. 
Yellon’s colleague Dr Sean Davidson, a Senior 
Research Fellow and Associate Director at the 
Hatter Cardiovascular Institute, was elected 
to investigate in detail the part played by 
mitochondria – cellular energy powerhouses 
fundamental to cell activity and survival – in 
this process. “Our team was instrumental in 
investigating the basic pro-survival signalling 
mechanisms involved in protection by 
recognising that the pathway converged 
on mitochondria,” recalls Davidson. “More 
specifically, Yellon identified the pro-survival 
kinases, coining them the ‘reperfusion injury 
salvage kinase (RISK)’ pathway.” Building upon 
this discovery, Yellon and Davidson went on to 
explore the relationship between mitochondria 
and the RISK pathway, and demonstrated that 
the permeability transition pore (PTP) of the 
inner mitochondrial membrane was directly 
involved in preconditioning. This has led them to 
propose that the PTP acts as the end-effector in 
the protection process, and infer that the RISK 
pathway and inhibition of PTP opening might 
serve as therapeutic targets in cardiac protection 
strategies to improve prognoses for acute heart 
attack patients. 
Using specialised medical imaging techniques, 
Yellon and Davidson are currently exploring the 
role of exosomes in mitochondrial protection 
against heart cell death. Exosomes are 
microvesicles measuring 30-100 nanometres in 
diameter and, present in most bodily fluids such 
as blood, saliva and urine, are thought to ferry 
proteins, messenger RNA and microRNA while 
protecting their cargo from the immune system 
and enzymatic degradation. The UCL researchers 
are testing the possibility that the transfer of 
exosomes and their cargo to cells may actually 
be core to intercellular communication, and so 
underlie the process of signalling from the limb to 
which non-invasive RIC is applied to the visceral 
organs. So far, in animal studies, the investigators 
have found that exosomes are highly protective 
of the heart, activating the same protective 
kinase pathways used in preconditioning. 
Intriguingly, it appears that the mechanism may 
be evolutionarily conserved across species. 
Yellon and Davidson’s objective is ultimately 
to exploit the innate survival mechanisms 
that prevent cell death and so myocardial 
injury from ischaemia-reperfusion. In this, 
they see clear potential for harnessing the 
abilities of exosomes by manipulating them 
to deliver specific proteins or by stimulating 
the production and transport of pro-survival 
exosomes in the body. “We are now learning 
what causes the release of exosomes from 
cells, what regulates their content, and how to 
exploit the proteins they carry to the advantage 
of cells under threat of injury,” Yellon enthuses. 
They also hope to realise the apparent potential 
of exosomes to exert protective effects on the 
heart in patients with co-morbidities such as 
diabetes to improve outcomes.
THE HEART OF THE MATTER 
In addition to these avenues of investigation, the 
Hatter Cardiovascular Institute is also carrying 
out two further studies related to non-invasive 
RIC. In light of the fact that certain biochemical 
changes and aspects of mitochondrial regulation 
play fundamental roles in the orchestration of 
cell death, the first project (with support from 
the UK Medical Research Council and the British 
Heart Foundation) is utilising multi-photon 
imaging to examine the response of myocardial 
calcium and mitochondria to ischaemia-
reperfusion injury. “This allows us to directly 
visualise what is happening inside the live 
heart,” explains Davidson. 
In the second project, investigators are also 
analysing the importance of the cytokine 
stromal cell-derived factor 1α (SDF-1α) 
messenger molecule in the process of heart 
protection during ischaemia and reperfusion. 
“This cytokine has dual activities, being an 
important regulator of stem cell homing 
to sites of myocardial injury, in addition to 
conferring direct protective effects in the 
setting of acute myocardial infarction,” Yellon 
elaborates. Having recently published an initial 
study suggesting that SDF-1α may play a role in 
RIC, Yellon and Davidson are now investigating 
whether SDF-1α is also carried by exosomes. 
Interest in the possibilities presented by RIC 
is now growing rapidly on a global scale, with 
an ever-increasing number of research groups 
attempting to test both the efficacy of the 
procedure and elucidate the mechanisms that 
underlie it. “A race is on around the world to 
try and be the first to identify the factor that 
signals from the limb to the heart,” reveal 
Yellon and Davidson. Whether or not the 
Hatter Cardiovascular Institute will ‘win’ 
this race remains to be seen; either way, it is 
certain humanity as a whole will benefit from 
the pioneering research they are conducting in 
this area.
The white in these tissue cross-sections shows the extent 
of damage caused to the heart by myocardial infarction. 
Without protection (left), the damage is extensive. With 
preconditioning (centre) and RIC (right), damage is 
significantly reduced.
A multi-photon image of cells within a live heart.
Whenever possible, experiments are performed on 
human heart tissue taken from patients undergoing 
surgery. However, since this can be difficult to come by, 
rodent models are also used to test novel procedures.
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ERICCA
EFFECT OF REMOTE ISCHAEMIC 
PRECONDITIONING ON CLINICAL 
OUTCOMES IN PATIENTS 
UNDERGOING CORONARY ARTERY 
BYPASS GRAFT SURGERY
OBJECTIVES 
To determine whether remote ischaemic 
preconditioning improves clinical outcomes after 
cardiac surgery.
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Dr Derek Hausenloy, Hatter Cardiovascular 
Institute at University College London
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DEREK YELLON is Professor of Molecular and 
Cellular Cardiology at University College London 
(UCL), Director of the Hatter Cardiovascular 
Institute at UCL Hospitals and Medical School 
and Programme Director (Cardiometabolic) for 
the NIHR Biomedical Research Centre at UCL 
Hospitals. He is also NIHR Senior Investigator, 
a member of the UK’s college of senior 
investigators, and is on the editorial board of a 
number of major cardiovascular journals. He has 
published in excess of 450 full papers and edited 
23 books.  
 
SEAN DAVIDSON obtained his PhD 
in Melbourne, Australia, on methods of 
protecting cells from heat stress. He undertook 
postdoctoral work at the École Normale 
Supérieure in Paris, then moved to London in 
1998 and is now Senior Research Fellow and 
Associate Director at the Hatter Cardiovascular 
Institute at UCL, where his focus is on 
developing methods to protect the heart from 
another type of stress – namely, ischaemia and 
reperfusion injury.
Source: The British Heart Foundation
CORONARY HEART DISEASE IS THE SINGLE LARGEST CAUSE OF DEATH IN THE UK
IT KILLS AROUND 1 IN 6 MEN AND 1 IN 10 WOMEN
SOMEONE DIES FROM A HEART ATTACK IN THE UK EVERY 7 MINUTES
INTELLIGENCE
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